{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:53:38Z","timestamp":1776938018962,"version":"3.51.4"},"reference-count":30,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2025,6,2]]},"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1136\/ejhpharm-2025-004552","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T02:50:20Z","timestamp":1749610220000},"page":"244-248","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Medication adherence in chronic myeloid leukemia: a hospital pharmacy-level analysis"],"prefix":"10.1136","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7103-3892","authenticated-orcid":false,"given":"Violeta","family":"Getova-Kolarova","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kamusheva","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Kokudeva","sequence":"additional","affiliation":[{"name":"National Specialized Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miglena","family":"Doneva","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilko","family":"Getov","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2026042302151372000_33.3.244.1","unstructured":"Bulgarian Medical Society for Haematology . Pharmaco-therapeutic guide to hematology. guidelines for the diagnosis and treatment of haematological diseases. 2019."},{"key":"2026042302151372000_33.3.244.2","unstructured":"National Care Institute . Cancer stat facts: leukemia \u2014 chronic myeloid leukemia (cml) [internet]. 2025. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html"},{"key":"2026042302151372000_33.3.244.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-022-03511-9","article-title":"Chronic myeloid leukemia: the cutting-edge evidence and things we should know","volume":"117","author":"Iriyama","year":"2023","journal-title":"Int J Hematol"},{"key":"2026042302151372000_33.3.244.4","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03117-7"},{"key":"2026042302151372000_33.3.244.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.006"},{"key":"2026042302151372000_33.3.244.6","unstructured":"Horne R , Weinman J . Concordance, adherence and compliance in medicine taking. 2005."},{"key":"2026042302151372000_33.3.244.7","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90014-4"},{"key":"2026042302151372000_33.3.244.8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5498\/wjp.v4.i2.30","article-title":"What\u2019s in a name? Compliance, adherence and concordance in chronic psychiatric disorders","volume":"4","author":"Chakrabarti","year":"2014","journal-title":"World J Psychiatry"},{"key":"2026042302151372000_33.3.244.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7339.690"},{"key":"2026042302151372000_33.3.244.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2004.00580.x"},{"key":"2026042302151372000_33.3.244.11","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/217047","article-title":"Medication Adherence Measures: An Overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed Res Int"},{"key":"2026042302151372000_33.3.244.12","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2147\/PPA.S92125","article-title":"Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment","volume":"9","author":"Kek\u00e4le","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"2026042302151372000_33.3.244.13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11899-021-00659-9","article-title":"A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center","volume":"16","author":"Canadeo","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"2026042302151372000_33.3.244.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2016.09.1414","article-title":"Relations between Adherence to Therapy and Quality of Life (Qol) In Cml Patients in Bulgaria","volume":"19","author":"Georgieva","year":"2016","journal-title":"Value Health"},{"key":"2026042302151372000_33.3.244.15","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3897\/pharmacia.70.e111923","article-title":"Analysis of the pharmacotherapeutic effectiveness of the tyrosine kinase inhibitors therapy in patients with Chronic Myeloid Leukemia in a single hematology center in Plovdiv, Bulgaria","volume":"70","author":"Goranova-Marinova","year":"2023","journal-title":"PHAR"},{"key":"2026042302151372000_33.3.244.16","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.170"},{"key":"2026042302151372000_33.3.244.17","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.2147\/PPA.S472478","article-title":"Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data","volume":"18","author":"Michiels","year":"2024","journal-title":"Patient Prefer Adherence"},{"key":"2026042302151372000_33.3.244.18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/03007995.2021.1876006","article-title":"Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life","volume":"37","author":"Santoleri","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2026042302151372000_33.3.244.19","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1177\/1078155220970616","article-title":"Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia","volume":"27","author":"Clark","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2026042302151372000_33.3.244.20","doi-asserted-by":"crossref","unstructured":"Ross XS , Gunn KM , Suppiah V , et al . A review of factors influencing non-adherence to oral antineoplastic drugs. Support Care Cancer 2020 Apr 25;28(9):4043\u201350. doi:10.1007\/s00520-020-05469-y","DOI":"10.1007\/s00520-020-05469-y"},{"key":"2026042302151372000_33.3.244.21","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.3324\/haematol.2022.280637","article-title":"Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China","volume":"107","author":"Chen","year":"2022","journal-title":"Haematologica"},{"key":"2026042302151372000_33.3.244.22","doi-asserted-by":"crossref","unstructured":"Nardi AE , Sancassiani F , Barrui V , et al . The Effects of Tyrosine Kinase Inhibitors (TKIs) in Monotherapy and with Add-on Treatments on Health-related Quality of Life of People with Chronic Myeloid Leukemia: A Systematic Review of Randomized-Controlled Trials. CPEMH 2023;19. doi:10.2174\/17450179-v17-e211118-2021-HT2-1910-12","DOI":"10.2174\/17450179-v17-e211118-2021-HT2-1910-12"},{"key":"2026042302151372000_33.3.244.23","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph182111045","article-title":"Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study","volume":"18","author":"Davis","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026042302151372000_33.3.244.24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejon.2020.101730","article-title":"Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies","volume":"45","author":"Hewison","year":"2020","journal-title":"Eur J Oncol Nurs"},{"key":"2026042302151372000_33.3.244.25","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211073576"},{"key":"2026042302151372000_33.3.244.26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.5414\/CP204259","article-title":"Prevalence of therapeutic drug monitoring and adherence to imatinib in chronic myeloid leukemia in Japan","volume":"60","author":"Kawabe","year":"2022","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2026042302151372000_33.3.244.27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cncr.35021","article-title":"Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia","volume":"130","author":"Efficace","year":"2024","journal-title":"Cancer"},{"key":"2026042302151372000_33.3.244.28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11096-020-01070-9","article-title":"Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital","volume":"43","author":"Lee","year":"2021","journal-title":"Int J Clin Pharm"},{"key":"2026042302151372000_33.3.244.29","doi-asserted-by":"crossref","first-page":"110847","DOI":"10.1016\/j.intimp.2023.110847","article-title":"Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia","volume":"124","author":"Cheng","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2026042302151372000_33.3.244.30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/COC.0000000000000700","article-title":"Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study","volume":"43","author":"Phuar","year":"2020","journal-title":"Am J Clin Oncol"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2025-004552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:16:07Z","timestamp":1776935767000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2025-004552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,23]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/ejhpharm-2025-004552"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2025-004552","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}